Research Reference
Teriparatide
FDA-approved recombinant PTH analog for osteoporosis
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Teriparatide (Forteo) is an FDA-approved recombinant parathyroid hormone (PTH 1-34) analog for osteoporosis that stimulates new bone formation.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 2 mg vial. Resulting concentration: 1 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 20 mcg | 2 units | 0.02 mL | SubQ, dailyFDA-approved dose (Forteo) |
| 40 mcg | 4 units | 0.04 mL | SubQ, dailyHigher research dose |
| 20 mcg | 2 units | 0.02 mL | SubQ, daily (cycled)Research-peptide protocol |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
FDA-approved teriparatide (Forteo) is supplied as a pre-filled pen device delivering 20 mcg per 80 mcL injection, requiring no reconstitution. Compounded research-peptide forms, when referenced, are supplied as a lyophilized powder in 2 mg or 5 mg vials.
For a 2 mg vial reconstituted with 2 mL of bacteriostatic water, the resulting concentration is 1 mg/mL; a 20 mcg dose draws to 2 units (0.02 mL) on a U-100 insulin syringe. For a 5 mg vial reconstituted with 2.5 mL, the concentration is 2 mg/mL; a 20 mcg dose draws to 1 unit (0.01 mL). Gently swirl — do not shake — to mix. Store reconstituted vials refrigerated at 2–8°C and use within the period specified by the compounding source.
Cycling Protocol
The FDA-approved Forteo protocol describes 20 mcg subcutaneously once daily for up to 2 years, after which a lifetime treatment limit is recommended due to the black-box warning of osteosarcoma observed in long-term rat studies. A subsequent off-drug period or transition to an antiresorptive agent is commonly described.
Community research-peptide protocols describe shorter cycles — for example 20 mcg daily for 8–12 weeks followed by an off period — though these depart from the FDA-approved labeling and lack large controlled trials supporting them.
Routes of Administration
Subcutaneous injection (FDA-approved route): Administered once daily into the thigh or abdomen. The Forteo pen delivers a fixed 20 mcg dose. Compounded research-peptide forms use the same subcutaneous route with an insulin syringe (29–31 gauge).
No other route is approved or commonly described for teriparatide; it is not administered orally (peptide degradation) or intravenously in standard protocols.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Bone Formation + Antiresorptive | Teriparatide followed by a bisphosphonate or SERM | Sequential: build bone, then preserve | | Anabolic Combination | Teriparatide + a bisphosphonate (concurrent) | Mixed anabolic/antiresorptive (studied in trials) |
The FDA label and clinical literature describe sequential or concurrent use with antiresorptive agents under medical supervision. Concurrent use of multiple anabolic agents is not standard practice.
Side Effects & Safety
- Orthostatic hypotension — transient, typically within 4 hours of the first few doses
- Nausea and dizziness — most common early in treatment
- Leg cramps — reported in clinical trials
- Injection-site reactions — redness or mild pain
- Hypercalcemia — possible at higher doses; monitoring recommended
- Black-box warning: osteosarcoma — observed in long-term, high-dose rat studies; the FDA imposes a lifetime treatment limit (typically 2 years of use)
Teriparatide is FDA-approved; compounded research-peptide forms are not FDA-approved and are sold for research purposes only.
Research Basis
Teriparatide is a recombinant 34-amino-acid N-terminal fragment of human parathyroid hormone (PTH 1-34).
FDA approval: Approved for osteoporosis in postmenopausal women and men at high risk for fracture, and for glucocorticoid-induced osteoporosis, based on fracture-reduction trials showing increased bone mineral density and reduced vertebral and nonvertebral fracture risk (Neer et al., 2001).
Anabolic mechanism: Intermittent (daily) PTH 1-34 stimulates osteoblast activity and new bone formation, in contrast to continuous endogenous PTH which is catabolic.
Lifetime limit: The 2-year treatment cap reflects the rat osteosarcoma finding; long-term human surveillance has not shown a confirmed increased risk, but the caution persists in labeling.